Explore this article's sources with AI
Follow PeptideMethods on Google
GLP-1 Cardiovascular Trials: 2026 Review
A 2026 review links five major cardiovascular, kidney and heart-failure trials, but each result belongs to a specific drug, population and endpoint.
Why we wrote this. One review puts several headline cardiovascular results side by side. We separated the populations and endpoints so the percentages are not mistaken for class effects.
In this article (6 sections)
A 2026 review of GLP-1-based therapies in cardiovascular disease enrolled no new participants. It reported no new patient outcomes, and the authors brought major cardiovascular, kidney and heart-failure trials together with mechanistic literature and guidelines published through July 2026[1]. Its useful lesson is about boundaries: SELECT, FLOW, SOUL, SUMMIT and SURPASS-CVOT studied different drugs, populations, comparators and endpoints. Their percentages cannot be combined into one class-wide promise.
What the GLP-1 cardiovascular review covered
The authors describe an expanding evidence base beyond glucose control in type 2 diabetes. Their review spans major adverse cardiovascular events, kidney outcomes and worsening heart failure[1]. That scope is broad, but each trial still answers a narrow question. A result for injectable semaglutide in people without diabetes does not establish the same effect for every GLP-1 receptor agonist. A heart-failure composite with tirzepatide is also different from a three-point cardiovascular-event composite.
The review is best read as a trial map. It does not pool participant-level data, run a new randomized comparison or rank medicines. The underlying event counts and comparators are needed to interpret each relative reduction.
SELECT tested semaglutide outside diabetes
SELECT randomized 17,604 adults aged 45 or older who had overweight or obesity and established cardiovascular disease, but no diabetes. With placebo as the comparator, weekly subcutaneous semaglutide 2.4 mg produced a primary composite event in 6.5% of participants, compared with 8.0% in the placebo group over a mean 39.8 months of follow-up. The composite covered cardiovascular death, nonfatal heart attack or nonfatal stroke. The hazard ratio was 0.80, reported as a 20% relative reduction[2].
The absolute difference in first primary events was 1.5 percentage points. Permanent treatment discontinuation because of adverse events occurred in 16.6% with semaglutide and 8.2% with placebo[2]. SELECT therefore supports one drug in one secondary-prevention population. It does not show primary prevention in people without established cardiovascular disease.
FLOW and SOUL asked different semaglutide questions
FLOW enrolled 3,533 people with type 2 diabetes and chronic kidney disease. Weekly semaglutide 1.0 mg reduced the primary kidney composite by 24% relative to placebo: 331 versus 410 first events, with a hazard ratio of 0.76. That composite included kidney failure, a sustained loss of kidney function, or death from kidney-related or cardiovascular causes. Major cardiovascular events were a confirmatory secondary outcome and were 18% lower[3]. The 24% headline is a kidney-composite result, so it should not be restated as a 24% reduction in heart attacks or strokes.
SOUL studied oral semaglutide in 9,650 people with type 2 diabetes plus atherosclerotic cardiovascular disease, chronic kidney disease or both. Three-point major cardiovascular events occurred in 12.0% with oral semaglutide and 13.8% with placebo, for a hazard ratio of 0.86[4]. The confirmatory secondary outcomes did not differ significantly. SOUL supplies drug-specific evidence for the oral formulation in a high-risk diabetes population; it does not erase formulation, population or endpoint differences across trials.
SUMMIT and SURPASS-CVOT define tirzepatide's evidence
SUMMIT randomized 731 people with obesity and heart failure with preserved ejection fraction to tirzepatide or placebo. Cardiovascular death or worsening heart failure occurred in 9.9% and 15.3%, respectively, with a hazard ratio of 0.62. Most of the separation came from fewer worsening heart-failure events. Cardiovascular deaths were 8 with tirzepatide and 5 with placebo, an imprecise comparison with a wide confidence interval[5]. The 38% relative reduction belongs to the composite, not cardiovascular death by itself.
SURPASS-CVOT answered another question. It compared tirzepatide with dulaglutide, rather than placebo, in people with type 2 diabetes and atherosclerotic cardiovascular disease. Three-point cardiovascular events occurred in 12.2% with tirzepatide and 13.1% with dulaglutide. Tirzepatide met the prespecified noninferiority test but did not meet superiority, with a hazard ratio of 0.92 and a 95.3% confidence interval from 0.83 to 1.01[6]. This supports cardiovascular safety relative to an active GLP-1 comparator. It does not prove that tirzepatide prevents more events than dulaglutide.
Mechanisms remain proposed, not proven
The review argues that several mechanisms beyond glucose lowering and weight loss may contribute to the observed outcomes[1]. Because the outcomes trials did not randomize participants to isolated mechanisms, changes in weight, glycemia or another marker can accompany fewer events without proving that the marker caused the benefit. The trials establish clinical effects for their tested interventions and populations; mechanistic explanations remain interpretations that need dedicated studies.
Manufacturer funding is also part of the evidence context. Novo Nordisk funded SELECT, FLOW and SOUL. Eli Lilly funded SUMMIT and SURPASS-CVOT. Randomization and adjudicated outcomes remain meaningful, while independent replication and longer follow-up still matter.
What we still do not know
This review cannot identify one best GLP-1-based therapy for cardiovascular disease. There is no single head-to-head trial spanning the populations and endpoints summarized here. Long-term safety, the size of benefit in lower-risk populations, and the mechanisms behind the observed effects remain open questions. Gastrointestinal adverse effects and treatment discontinuation also affect how trial efficacy translates into routine care.
These results are not a reason to choose or change treatment without clinical review. Eligibility, formulation, kidney function, heart-failure phenotype, existing cardiovascular disease and adverse-effect risk all change how a trial applies to one person. A clinician can match those details to current product information and local guidance.
Medical disclaimer: This article is for educational and journalistic purposes only and does not constitute medical advice. Peptides discussed may be classified as prescription medicines or research chemicals depending on your jurisdiction. Always consult a qualified healthcare professional before using any peptide product. PeptideMethods.com does not sell, distribute, or facilitate the sale of any peptide product.
Frequently asked
Did the 2026 cardiovascular review enroll patients?
No. It reviewed existing randomized trials, mechanistic studies and guidelines through July 2026. The participant counts and clinical outcomes come from the original trials.
Do these trials prove a cardiovascular benefit for every GLP-1 drug?
No. SELECT, FLOW and SOUL tested semaglutide in different populations and formulations. SUMMIT and SURPASS-CVOT tested tirzepatide with different comparators and endpoints. Each result remains drug-specific and population-specific.
Did SURPASS-CVOT show tirzepatide was better than dulaglutide?
No. Tirzepatide met the trial's noninferiority criterion for major cardiovascular events but did not meet the superiority criterion. The result supports that it was not unacceptably worse under the prespecified margin, not that it prevented more events.
Sources
- [1]Jang R et al. GLP-1-based therapies in cardiovascular disease: outcomes, mechanisms, and emerging clinical applications. European Journal of Clinical Pharmacology. 2026. PMID 42918905.Tier 1 · primary↩
- [2]Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. New England Journal of Medicine. 2023. PMID 37952131.Tier 1 · primary↩
- [3]Perkovic V et al. Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes. New England Journal of Medicine. 2024. PMID 38785209.Tier 1 · primary↩
- [4]McGuire DK et al. Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes. New England Journal of Medicine. 2025. PMID 40162642.Tier 1 · primary↩
- [5]Packer M et al. Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity. New England Journal of Medicine. 2025. PMID 39555826.Tier 1 · primary↩
- [6]Nicholls SJ et al. Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes. New England Journal of Medicine. 2025. PMID 41406444.Tier 1 · primary↩
No revisions yet. First published .